ABSTRACT
The complexity and expense in identifying an ideal allogeneic hematopoietic stem cell donor is due to the high polymorphism of the HLA genes. Every HLA antigen mismatch between the donor and the recipient adversely affects the success of allogeneic transplantation. Lately, many laboratories and donor centers are now adopting next-generation sequencing (NGS) approaches for patients and donors. The criteria and strategy used in selecting the best donor for patients with autoimmune diseases differs from those used for hematologic disorders or malignancies since there is no benefit from graft versus host disease (GvHD) and its associated graft versus leukemia effect.
